DUBLIN–(BUSINESS WIRE)–The “Small
Molecule Drug Discovery Market – Growth, Trends, and Forecast (2019 –
2024)” report has been added to ResearchAndMarkets.com’s
offering.
The global small molecule drug discovery market was valued at USD
29,363.85 million in 2018, and is estimated to be valued at USD
46,882.22 million in 2024, witnessing a CAGR of 8.11%.
The increasing applications of small molecule drugs for the treatment of
chronic diseases are leading to the increased demand for these drugs in
the market. Moreover, due to the aforementioned factors, small molecule
drugs dominate the biologics in the current healthcare market.
The preference of small molecules, along with the increasing disease
complications and technological advancements, has led major players to
increase their R&D expenditure, which is further acting as the major
growth driver for the global small molecule drug discovery market.
The global small molecule drug discovery market is subject to impacts
from political situations. The policy implemented by the government has
the capability to either amplify or diminish the market.
Key Market Trends
Lead Optimization is Expected to hold its Highest Market Share in
the Process/Phase Segment
In the process/phase segment of the market, lead optimization is
believed to have the largest market size and is expected to witness a
CAGR of 7.93% during the forecast period.
The process of lead optimization is achieved by modifying the selected
small molecule, in order to improve efficacy and therapeutic value. Once
the pharmacophore, which consists of relevant groups on a molecule that
interact with a receptor and are responsible for the biological
activity, is identified, it is subjected to functional group
modification. Various changes are made to the initial compound and the
therapeutic index is measured.
Rapid usage of in-vitro experiments, accompanied with computation
procedures in early drug discovery for selection of compounds with more
promising ADME, i.e., absorption, distribution, metabolism, and
excretion, and toxicological profiles, is expected to drive the market
studied.
The rise in cancer and other neglected diseases is encouraging
investments in lead optimization for enhanced therapeutic value, in
order to provide patients with efficient and targeted therapies.
North America Dominates the Market and is Expected to follow the
Same Trend in the Forecast Period
North America currently dominates the market for small molecule drug
discovery and is expected to continue its stronghold for a few more
years. According to FDA, in 2016, the Center for Drug Evaluation and
Research (CDER) approved 22 novel drugs, either as new molecular
entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic
biologics under Biologics License Applications (BLAs). Overall, 31,468
patients participated in these trials. This shows that the United States
is focusing on R&D activities to meet the increasing demands of its
citizens for better and effective drugs.
The rising focus on the R&D in the country is expected to propel the
market growth in the future.
Competitive Landscape
The small molecule drug discovery market is moderately competitive and
consists of several major players. In terms of market share, few of the
major players currently dominate the market. However, with technological
advancements and product innovations, mid-size to smaller companies are
increasing their market presence by introducing new ingredients with
fewer prices.
Companies, like Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co.,
Boehringer Ingelheim GmbH, and GlaxoSmithKline, hold the substantial
share in the market.
Key Topics Covered
1 Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Demand for Small Molecule Drugs
4.2.2 Dominance of Small Molecules in the Market
4.2.3 Increasing Number of Contract Organizations for R&D
4.2.4 Small Molecules in Treatment of Chronic Diseases
4.2.5 High R&D Expenditure in Small Molecule Drugs
4.3 Market Restraints
4.3.1 High Drug Development Cost
4.3.2 Strict Regulations
4.4 Porter’s Five Forces Analysis
5 Market Segmentation
5.1 By Therapeutic Area
5.1.1 Oncology
5.1.2 Central Nervous System
5.1.3 Cardiovascular
5.1.4 Respiratory
5.1.5 Metabolic Disorders
5.1.6 Gastrointestinal
5.1.7 Orthopedics
5.1.8 Anti-infective
5.1.9 Dermatology
5.1.10 Immunology
5.1.11 Other Therapeutic Areas
5.2 By Process/Phase
5.2.1 Target Id/Validation
5.2.2 Hit Generation and Selection
5.2.3 Lead Identification
5.2.4 Lead Optimization
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East & Africa
5.3.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Merck & Co.
6.1.4 Boehringer Ingelheim GmbH
6.1.5 GlaxoSmithKline PLC
6.1.6 AstraZeneca
6.1.7 Johnson & Johnson
6.1.8 Gilead Sciences Inc.
6.1.9 Teva Pharmaceuticals
6.1.10 Teva Pharmaceutical Industries Ltd.
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/gdsxpt/global_small?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery